Karyopharm Therapeutics (KPTI) Short-term Investments (2014 - 2025)

Karyopharm Therapeutics has reported Short-term Investments for 12 years, with the latest figure at $3.2 million in Q4 2025.

• For the quarter ending Q4 2025, Short-term Investments fell 93.07% year-over-year to $3.2 million; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (down 93.07% YoY), and the FY2025 full-year result was $3.2 million, down 93.07% from the prior year.
• Short-term Investments for Q4 2025 stood at $3.2 million, down from $8.2 million in the prior quarter.
• The five-year high for Short-term Investments was $176.3 million in Q1 2023, with the low at $3.2 million in Q4 2025.
• Historically, Short-term Investments has averaged $84.0 million across 5 years, with a median of $72.2 million in 2022.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 274.2% — and 2025, when it slumped 93.07%.
• Karyopharm Therapeutics' Short-term Investments stood at $38.2 million in 2021, then surged by 274.2% to $142.8 million in 2022, then slipped by 2.5% to $139.2 million in 2023, then slumped by 66.79% to $46.2 million in 2024, then tumbled by 93.07% to $3.2 million in 2025.
• The last three Short-term Investments figures came in at $3.2 million (Q4 2025), $8.2 million (Q3 2025), and $13.0 million (Q2 2025), per Business Quant data.